BioNexus Gene Lab Corp. (BGLC) Stock Analysis & Investment Frameworks
BioNexus Gene Lab Corp. (BGLC) stock analysis on Invetso. Review BioNexus Gene Lab Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
BioNexus Gene Lab Corp. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Industrials
- Industry: Industrial - Distribution
- Country: MY
BioNexus Gene Lab Corp. Key Financial Metrics
- Market Cap: $2.88M
- Revenue: $7.42M
- ROE: -32.91%
- ROIC: -32.45%
- Dividend Yield: N/A
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
BioNexus Gene Lab Corp. Investment Frameworks
Invetso analyzes BioNexus Gene Lab Corp. (BGLC) across the following frameworks:
- BioNexus Gene Lab Corp. 10Y Growth Potential
- BioNexus Gene Lab Corp. Scenario Analysis
- BioNexus Gene Lab Corp. Risks & Opportunities
- BioNexus Gene Lab Corp. Economic Moat
- BioNexus Gene Lab Corp. Business Model
- BioNexus Gene Lab Corp. Management
- BioNexus Gene Lab Corp. SWOT Analysis
- BioNexus Gene Lab Corp. Porter's 5 Forces
- BioNexus Gene Lab Corp. PESTLE Analysis
- BioNexus Gene Lab Corp. ESG Analysis